Then, in vivo and in vitro models of MTAP‐deficient gliomas coexisting with neurons or glial cells were constructed for evaluating the effectiveness of the anti‐tumor effects of MRTX1719 in this setting. This evidence concerns the gene MTAP and central nervous system cancer.